Longest Clinical Study of Smegglutide Published: Continuous Four Years of Medication Can Maintain 10% Weight Loss
JESUS60
发表于 2024-5-14 17:49:02
1276
0
0
[The longest clinical study of Smeglutide was published: it can maintain a weight loss of 10% after four years of medication] Star weight loss therapy Smeglutide manufacturer Novo Nordisk displayed the longest clinical follow-up data of the company so far at the European Obesity Conference on May 14, local time. The results showed that overweight and obese patients with heart disease but no diabetes could still maintain an average weight loss of 10% after four years of continuous treatment with Wegovy, a weight loss drug of Smeglutide.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- How effective is the drug supply process initiated by Novo Nordisk for the approved slimming version of Smegglutide in China?
- Will Smegglutide's indications for treating obesity participate in this year's national medical insurance negotiations? Novo Nordisk responded by stating that they will immediately initiate internet access and hospital admissions in various regions
- Will the reduced weight version of Smegglutide be limited in supply to the Chinese market? Novo Nordisk responds
- The Battle of Weight Loss Drugs Begins: Smegglutide's Obesity Indications Approved in China
- After nearly four years, Ping An of China has passively consolidated its holdings in Lufax, with a shareholding ratio expected to increase to 56.82%, stating that it has no intention of privatization
- Zaiding Medicine: Clinical study of KarXT for the treatment of schizophrenia completed, enrolled patients from mainland China
- Poor performance, Nike changes leadership: retired veteran of four years appointed as new CEO
- Boeing and union reach agreement on latest four-year contract plan, with salary increase of 38% within four years
- Novo Nordisk warns of the risk of compound generic semaglutide, which has caused 10 deaths and 100 hospitalizations
- Weight reducing version of semaglutide officially launched in China
-
知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
- caffycat
- 昨天 11:18
- 支持
- 反对
- 回复
- 收藏
-
每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
- star8699
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
- goodfriendboy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
- 3233340
- 昨天 17:06
- 支持
- 反对
- 回复
- 收藏